Abilify (aripiprazole) Tablets, Orally Disintegrating Tablets, Oral Solution, and Injection for INTRAMUSCULAR USE ONLY
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
January 2016
ADVERSE REACTIONS
Postmarketing Experience
addition of pathological gambling and hiccups
...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Abilify | Drugs & Pharmacology